New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease

被引:118
作者
Mason, R. Preston [1 ,2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Dept Med, Boston, MA 02115 USA
[2] Elucida Res LLC, Beverly, MA 01915 USA
关键词
Atherosclerosis; Triglycerides; Lipoproteins; Omega-3 fatty acids; Cholesterol; Eicosapentaenoic; DENSITY-LIPOPROTEIN PARTICLES; CHOLESTEROL DOMAIN FORMATION; OMEGA-3; DIETARY-SUPPLEMENTS; POLYUNSATURATED FATTY-ACIDS; HIGH TRIGLYCERIDE LEVELS; CORONARY-HEART-DISEASE; ESTER AMR101 THERAPY; EICOSAPENTAENOIC ACID; ICOSAPENT ETHYL; DOCOSAHEXAENOIC ACID;
D O I
10.1007/s11883-019-0762-1
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk. Genetic and epidemiologic studies have shown that elevated fasting TG levels are associated with incident cardiovascular events. At effective doses, omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels but may have additional atheroprotective properties compared to other TG-lowering therapies such as niacin and fibrates. The purpose of this review is to evaluate mechanisms related to the potential benefits of omega-3 fatty acids in atherothrombotic disease. Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day). A large randomized trial with a prescription EPA-only formulation was shown to reduce a composite of cardiovascular events by 25% in statin-treated patients with established cardiovascular disease or diabetes and other CV risk factors. EPA and DHA have distinct tissue distributions as well as disparate effects on membrane structure and lipid dynamics, rates of lipid oxidation, and signal transduction pathways. Compared to other TG-lowering therapies, EPA has been found to inhibit cholesterol crystal formation, inflammation, and oxidative modification of atherogenic lipoprotein particles. The anti-inflammatory and endothelial benefits of EPA are enhanced in combination with a statin. Omega-3 fatty acids like EPA only at a pharmacologic dose reduce fasting TG and interfere with mechanisms of atherosclerosis that results in reduced cardiovascular events. Additional mechanistic trials will provide further insights into their role in reducing cardiovascular risk in subjects with well-managed LDL-C but elevated TG levels.
引用
收藏
页数:11
相关论文
共 84 条
[1]   Cholesterol crystals cause mechanical damage to biological membranes: A proposed mechanism of plaque rupture and erosion leading to arterial thrombosis [J].
Abela, GS ;
Aziz, K .
CLINICAL CARDIOLOGY, 2005, 28 (09) :413-420
[2]   Small Dense LDL Cholesterol and Coronary Heart Disease: Results from the Framingham Offspring Study [J].
Ai, Masumi ;
Otokozawa, Seiko ;
Asztalos, Bela F. ;
Ito, Yasuki ;
Nakajima, Katsuyuki ;
White, Charles C. ;
Cupples, L. Adrienne ;
Wilson, Peter W. ;
Schaefer, Ernst J. .
CLINICAL CHEMISTRY, 2010, 56 (06) :967-976
[3]   Oxidation of Marine Omega-3 Supplements and Human Health [J].
Albert, Benjamin B. ;
Cameron-Smith, David ;
Hofman, Paul L. ;
Cutfield, Wayne S. .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[4]  
[Anonymous], 2008, NATL HLTH STAT REP
[5]   Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) [J].
Ballantyne, Christie M. ;
Bays, Harold E. ;
Kastelein, John J. ;
Stein, Evan ;
Isaacsohn, Jonathan L. ;
Braeckman, Rene A. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (07) :984-992
[6]   Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies [J].
Bays, Harold E. ;
Ballantyne, Christie M. ;
Braeckman, Rene A. ;
Stirtan, William G. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2013, 13 (01) :37-46
[7]   Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) [J].
Bays, Harold E. ;
Ballantyne, Christie M. ;
Kastelein, John J. ;
Isaacsohn, Jonathan L. ;
Braeckman, Rene A. ;
Soni, Paresh N. .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (05) :682-690
[8]   Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].
Bhatt, Deepak L. ;
Steg, P. Gabriel ;
Miller, Michael ;
Brinton, Eliot A. ;
Jacobson, Terry A. ;
Ketchum, Steven B. ;
Doyle, Ralph T., Jr. ;
Juliano, Rebecca A. ;
Jiao, Lixia ;
Granowitz, Craig ;
Tardif, Jean-Claude ;
Ballantyne, Christie M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22
[9]   Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial [J].
Bhatt, Deepak L. ;
Steg, Ph. Gabriel ;
Brinton, Eliot A. ;
Jacobson, Terry A. ;
Miller, Michael ;
Tardif, Jean-Claude ;
Ketchum, Steven B. ;
Doyle, Ralph T., Jr. ;
Murphy, Sabina A. ;
Soni, Paresh N. ;
Braeckman, Rene A. ;
Juliano, Rebecca A. ;
Ballantyne, Christie M. .
CLINICAL CARDIOLOGY, 2017, 40 (03) :138-148
[10]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267